NCT00160875View on ClinicalTrials.gov

Pre-operative Chemo (CPT11, Cisplatin), Radiotherapy, Plus Surgery for Resectable Esophageal Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Esophageal Cancer
Interventions
DRUG

Irinotecan hydrochloride trihydrate

Irinotecan (65mg/m2) weeks 1-2, 4-5, 7-8

DRUG

Cisplatin

Cisplatin (30 mg/m2) weeks 1-2, 4-5, 7-8

Trial Locations (1)

M5G 2M9

University Health Network, Toronto

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University Health Network, Toronto

OTHER